论文部分内容阅读
目的观察分析紫杉醇、奈达铂联合化疗治疗晚期食管癌的临床疗效及不良反应。方法回顾性分析自2009年3月至2011年6月进行治疗的48例晚期食管癌患者,临床分期Ⅲ期27例,Ⅳ期21例;化疗方案:紫杉醇(150±25)mg/m2,d1,奈达铂(90±10)mg/m2,d1;21 d为1个周期,2个周期后评价疗效。最多化疗6个周期。结果48例均至少完成2个周期化疗,可评价疗效。共完成176个疗程,平均每例为3.67个疗程。结果 1例CR,26例PR,12例SD,9例PD;有效率为56.25%,疾病控制率81.25%。不良反应主要为骨髓抑制、脱发、关节肌肉疼痛,未出现严重肝肾功能损害情况。结论紫杉醇联合奈达铂治疗晚期食管癌有较好的临床疗效,且安全性较高。
Objective To observe the clinical efficacy and side effects of paclitaxel, nedaplatin combined with chemotherapy in the treatment of advanced esophageal cancer. Methods A total of 48 patients with advanced esophageal cancer treated from March 2009 to June 2011 were retrospectively analyzed. The clinical stage was stage Ⅲ in 27 cases and stage Ⅳ in 21 cases. The chemotherapy regimen was paclitaxel (150 ± 25) mg / m2, d1 , Nedaplatin (90 ± 10) mg / m2, d1; 21 d for a cycle, after 2 cycles evaluation of efficacy. Up to 6 cycles of chemotherapy. Results 48 cases completed at least 2 cycles of chemotherapy, can evaluate the efficacy. A total of 176 courses were completed, with an average of 3.67 courses per case. Results One patient had CR, 26 patients had PR, 12 patients had SD and 9 patients had PD. The effective rate was 56.25% and the disease control rate was 81.25%. Adverse reactions mainly bone marrow suppression, hair loss, joint and muscle pain, no serious liver and kidney dysfunction. Conclusion paclitaxel combined with nedaplatin in the treatment of advanced esophageal cancer has a better clinical efficacy and safety.